From Yahoo Finance: 2025-03-27 13:29:00

Novo Nordisk shares have dropped 25% in March, facing their biggest monthly decline since July 2002, as concerns grow over losing ground to U.S. rival Eli Lilly in the obesity drug market. Despite doubling sales of weight-loss injection Wegovy last year, Novo’s market value has halved since last summer.

Investors and analysts are worried about Novo’s ability to maintain its position in the obesity market after Lilly’s Zepbound showed greater weight loss in trials than Wegovy. Weekly U.S. prescription data shows Zepbound prescriptions surpassing Wegovy by 80,000 per week, with stagnant Wegovy sales despite increased supply to the U.S. market.

Trials of Novo’s next-generation obesity drug CagriSema have also underperformed, adding to concerns about the company’s future. Analysts like Per Hansen from Nordnet describe the follow-up to a disappointing end of 2024 as “terrible” in Q1 2025. Additionally, U.S. tariffs threaten the pharma industry, compounding Novo’s challenges.



Read more at Yahoo Finance: Novo shares on track for biggest monthly fall since 2002, investor worries grow